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Editorial
Importance of Awareness of Adverse Drug
Reaction Reporting During the COVID-19
Pandemic
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Description

Health care professionals hold the responsibility of reporting any adverse drug reactions in
order to learn about new therapy and how best to safely care for our patients. The information derived from case publications and FDA MedWatch reports are essential to accumulate
information and increase awareness for the possible risks of new drugs.
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What is certain is that we are uncertain. During
this unprecedented time of the COVID-19
pandemic, treatment modalities, transmission
best practices and care for COVID-19 patients
have fluctuated frequently. In a time where the
answer is not readily available, we are required
to uphold our professional obligation to ensure
we learn and practice based on all available
information.
Since the start of the pandemic in early 2020,
the world of healthcare has seen change unlike
any other in these modern times. Treatment
guidance has changed drastically, sometimes
day to day. The reason behind this is, as we
learn more, we are able to shift decision-making to the new best practices to care for patients with a virus that was not previously
known.
In the beginning of the pandemic access to one
of the treatment options, an anti-viral agent
called remdesivir was limited. Eventually there
was an Emergency Use Authorization (EUA)
for the therapy, as it did not hold a current
approved indication for COVID-19.1 In knowing this medication had not been studied for
this indication and subsequently did not yet

have approval for it, health care providers had
a greater responsibility to keep a close eye on
therapy.
One of the ways to monitor this particular new
therapy as health care providers is through
reports of unexpected or unwanted reactions
to the medication. This is known as an adverse
drug reaction. Since remdesivir has not been
previously recommended or administered
for this indication—reporting of any adverse
reactions and learning as we go becomes imperative. This therapy is being used across the
globe and there are processes in place for these
reports to be shared to understand more about
possible risks or undesired outcomes.
Within each facility in a healthcare system,
there is a process for reporting adverse drug
reactions. The issue then becomes how this
information is shared with other facilities and
healthcare systems caring for the same types
of patients with this therapy. The U.S. Food
and Drug Administration (FDA) MedWatch is a
reporting program for adverse events.2 Health
professionals and patients can submit reports.
This reporting is voluntary and can help the
FDA identify previously unknown risks for med-
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ications or medical products.
You may think that the reporting of these adverse drug reactions would consistently occur.
In reality, reporting of adverse reactions are not
always common. Facilities operating under a
“Just Culture” find themselves in the best position to increase reporting. A “Just Culture” is
the mentality that there is support in an organization for reporting of issues and no punitive
action toward the reporter.
The Institute of Safe Medication Practices
(ISMP) is a great resource for patient safety
and best practices to ensure safe use of medicine. In organizations known to utilize support
from ISMP best practices, a “Just Culture” is
common and there is a healthy relationship
with reporting adverse drug reactions. We can
see how the reporting of reactions is necessary
and that when reports are accumulated and
monitored for trends reporting can help shape
practice and care of patients.
ISMP recently published an acute care medication safety alert newsletter with the main
article focusing on reported medication errors
with remdesivir use under the EUA.3 Errors
with wrong formulation, wrong preparation
and incorrect storage have all been reported.3
Recently, the final report for remdesivir was
published,4 and remdesivir was approved by the
FDA for treatment of adult and pediatric patients over 12 years of age and weighing at least
40 kilograms for the treatment of COVID-19
requiring hospitalization.4 As part of the EUA,
which still exists after the FDA approval for
certain indications, adverse drug reaction
reporting (including errors) to FDA MedWatch
is required of the health care provider within 7
days of the event.
As mentioned in the beginning of this article,
dramatic changes in therapy for treatment of
COVID-19 continues. Remdesivir therapy has
already shifted in terms of options for treatment of the infection. Recently, in November
2020, baricitinib was approved under an EUA to
be used in combination with remdesivir for the
treatment of COVID-19 in hospitalized adult
and pediatric patients requiring supplemental
oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).5
Two new medications have now been approved
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under EUAs.6,7 Also in November, bamlanivimab
was approved for the treatment of mild to
moderate COVID-19 in adult and pediatric
patients.6 It is important to note, bamlanivimab
is not approved for hospitalized patients.6 The
other therapy recently given an EUA in November is casirivimab and imdevimab, which must
be administered together for the treatment of
COVID-19 in adults and pediatric patients and
also is not authorized for hospitalized patients.7
With treatment options growing, the need for
reporting of any adverse reactions does not
diminish but increases. Treatment of COVID-19
in many different settings only furthers the
need for reporting, as the reactions may not be
witnessed by the same health care providers in
the inpatient and outpatient settings. In some
instances in the outpatient setting, patients
should be educated to submit a report to FDA
MedWatch.1
As health care professionals who may prepare, dispense and/or administer and monitor
patients receiving these new agents, we hold
the responsibility of reporting any adverse
drug reactions to continue to learn about these
therapies and how best to safely care for our
patients.8 Reporting should follow local internal reporting system process as well as FDA
MedWatch. Especially amidst pandemic, every
report is valuable. Case studies are compiled
with new information, including adverse reactions, on patients treated with remdesivir and
other recent EAU therapies. All of this information is needed to continue treatment forward
and hold patient safety in the highest regard
while fighting against the pandemic.
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